Form D · Biotechnology

Praesidia Biotherapeutics, Inc.

Arlington, MA · CIK 0001877990

Offering snapshot reported Jul 17, 2024 · SEC filing

Reported sold
$7.42M
Offering amount: $15M
Investors reported
52
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Mar 25, 2024
As reported in this filing

Fundraising history

Reported sold
Reported amount sold by Form D filing date$0$3.71M$7.42MApr 8, 2024: $500,000.00Apr 8, 2024Apr 11, 2024: $5,000,000.00Jul 17, 2024: $7,420,000.00Jul 17, 2024

Dates are filing dates, not cash receipt dates. Decreases are reported revisions, not evidence of withdrawals. Separate offering histories are not added together.

What changed?

Latest filing versus its linked predecessor, where available.

  • Reported sold$5,000,000 → $7,420,000
  • Reported investors1 → 52
  • Minimum accepted$100,000 → $0

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Jul 17, 2024Amendment$7,420,000$2,420,000vs Apr 11, 202452SEC filing
Apr 11, 2024Amendment$5,000,000$4,500,000vs Apr 8, 20241SEC filing
Apr 8, 2024Initial$500,000No comparison1SEC filing
Aug 23, 2022Amendment$4,000,000$0vs Aug 12, 202155SEC filing
Aug 12, 2021Initial$4,000,000No comparisonNot reportedSEC filing

Offering details

Securities
Security to be acquired
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$310K (estimated)
Finders' fees
$0
Form D file number
021-509890
The amount payable will depend on the amount sold and the composition of the investors.

Sales compensation recipients

Scroll to see all columns →

RecipientCRDAssociated broker-dealer
Wilmington Capital Securities, LLC133839

Source: Form D, filed Jul 17, 2024. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Sohang Chatterjee Director, Executive
Martin Lehr Director
Pradip Majumder Executive
John Ripple Director
Shawn Titcomb Director

Issuer details

Industry: Biotechnology (See others in industry)

Address:
1167 Massachusetts Ave.
Arlington, MA, 02476